Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees

Blood

Volumn 114, Issue 20, 2009, Pages 4477-7785

  Varghese, Bindu ^a   Widman, Adam ^a   Do, James ^a   Taidi, Behnaz ^a   Czerwinski, Debra K ^a   Timmerman, John ^b   Levy, Shoshana ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; LYMPHOMA; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TUMOR IMMUNITY; ANIMAL; B CELL LYMPHOMA; BAGG ALBINO MOUSE; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE MUTANT; TUMOR ESCAPE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; TUMOR ESCAPE;

EID: 73349128756     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-223263     Document Type: Article

References (35)

1. Varghese B, Taidi B, Widman A, Do J, Levy R. Generation of CD8 T cell-mediated protective immunity against tumor escapees [abstract]. Blood. 2008;112:2623.
2. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306(9):517-522.
3. Maloney DG, Brown S, Czerwinski DK, et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood. 1992;80(6):1502-1510.
4. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood. 1998;92(4):1184-1190.
5. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev. 2008;60(7):795-804.
6. Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179(4):2493-2500.
7. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma. 1985;4(3):191-209.
8. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol. 2008;181(6):4131-4140.
9. Carroll WL, Lowder JN, Streifer R, Warnke R, Levy S, Levy R. Idiotype variant cell populations in patients with B cell lymphoma. J Exp Med. 164(5):1566-1580, 1986.
10. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma: a study of hybridoma class switch variants. J Immunol. 1986;136(3):1123-1130.
11. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76(3):519-529.
12. Mizuguchi J, Tsang W, Morrison SL, Beaven MA, Paul WE. Membrane IgM, IgD, and IgG act as signal transmission molecules in a series of B lymphomas. J Immunol. 1986;137(7):2162-2167.
13. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985;65(6):1349-1363.
14. Kon S. [Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody]. Gan To Kagaku Ryoho. 1988;15(5):1685-1692.
15. Vuist WM, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood. 1994;83(4):899-906.
16. Levy R, Miller RA. Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst Monogr. 1990(10):61-68.
17. Brown SL, Miller RA, Horning SJ, et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with interferon. Blood. 1989;73(3):651-661.
18. Weng WK, Czerwinski D, Levy R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood. 2007;109(3):951-953.
19. Cleary ML, Meeker TC, Levy S, et al. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell. 1986;44(1):97-106.
20. Warren TL, Dahle CE, Weiner GJ. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma. 2000;1(1):57-61.
21. Saha A, Baral RN, Chatterjee SK, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother. 2006;55(5):515-527.
22. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997;89(8):2994-2998.
23. van Ojik HH, Bevaart L, Dahle CE, et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 2003;63(17):5595-5600.
24. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther. 2006;5(8):2106-2114.
25. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/βinducible gene expression, without significant toxicity. Blood. 2005;105(2):489-495.
26. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644-1652.
27. Gopal AK, Pagel JM, Hedin N, Press OW. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood. 2004;103(9):3516-3520.
28. Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol. 1998;10(4):287-297.
29. Cerveny CG, Law CL, McCormick RS, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia. 2005;19(9):1648-1655.
30. Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005;65(18):8331-8338.
31. Ward RE, McNamara-Ward M, Webb CF, et al. Regulation of an idiotype+ B cell lymphoma: effects of antigen and anti-idiotopic antibodies on proliferation and Ig secretion. J Immunol. 1988;141(1):340-346.
32. Jahrsdorfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol. 2001;69(1):81-88.
33. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res. 2005;11(4):1490-1499.
34. Reid GS, She K, Terrett L, Food MR, Trudeau JD, Schultz KR. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood. 2005;105(9):3641-3647.
35. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000;95(3):999-1006.